Table 1.

Epidemiologic characteristics, therapy, and immune phenotype of 159 patients in Italian areas with a high incidence of COVID-19

CharacteristicsValue
Age, yr
 Median (range)12.5 (2–28)
Sex, n (%)
 Male108 (68)
 Female51 (32)
Median of months since last anti-CD20 Ab administration (range)18 (1–63)
Median of total anti-CD20 infusions, n (range)2 (1–11)
Ongoing immunosuppressive therapies, n (%)
 None105 (66)
 Steroids18 (11)
 CNI14 (9)
 MMF9 (6)
 Steroids and MMF7 (4)
 Steroids and MMF and CNI6 (4)
Proteinuria (g/24 h)
 Median (range)1.5 (0.1–6.8)
RAASi, n (%)2 (1)
IgG (mg/dl), median (range)a675 (79–1425)
Pts with IgG ≤650 mg/dl, n (%)74 (46)
Circulating CD19+ B cells (/μl)b
 Median (range)328 (0–1275)
CD4/CD8 T cells, median (range)c1.5 (0.4–2.5)
Neutrophils (×103/μl), median (range)d4.5 (1.6–9.1)
Natural killer (%), median (range)e9.2 (1–23)
Pts with natural killer ≤6%, n (%)64 (40)
  • COVID-19, coronavirus disease 2019; Ab, antibody; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil; RAASi, renin-angiotensin-aldosterone system inhibitor; Pts, patients.

  • a Normal range for IgG: 650–2400 mg/dl.

  • b Normal range for CD19+ B cells: 140–900/μl.

  • c Normal range for CD4/CD8: 0.9–3.5.

  • d Normal range for neutrophils: 2.1–6.4 × 103/μl.

  • e Normal range for natural killer cells: 6%–27%.